Biogen Inc. (BIIB) Shares Bought by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,948 shares of the biotechnology company’s stock after acquiring an additional 520 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Biogen were worth $1,862,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Carroll Financial Associates Inc. lifted its stake in Biogen by 1.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 6 shares in the last quarter. RMB Capital Management LLC lifted its stake in Biogen by 1.1% in the 1st quarter. RMB Capital Management LLC now owns 814 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 9 shares in the last quarter. New Amsterdam Partners LLC NY lifted its stake in Biogen by 0.8% in the 2nd quarter. New Amsterdam Partners LLC NY now owns 1,471 shares of the biotechnology company’s stock worth $399,000 after acquiring an additional 11 shares in the last quarter. Alta Capital Management LLC lifted its stake in Biogen by 0.8% in the 2nd quarter. Alta Capital Management LLC now owns 1,880 shares of the biotechnology company’s stock worth $510,000 after acquiring an additional 15 shares in the last quarter. Finally, Bienville Capital Management LLC lifted its stake in Biogen by 2.2% in the 2nd quarter. Bienville Capital Management LLC now owns 880 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 19 shares in the last quarter. 88.28% of the stock is owned by hedge funds and other institutional investors.

Biogen Inc. (NASDAQ:BIIB) opened at $313.30 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. Biogen Inc. has a 52-week low of $244.28 and a 52-week high of $348.84. The stock has a market capitalization of $66,397.40, a price-to-earnings ratio of 14.54, a price-to-earnings-growth ratio of 1.96 and a beta of 0.72.

Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.70 by $0.61. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $5.19 EPS. equities research analysts expect that Biogen Inc. will post 22.03 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Biogen Inc. (BIIB) Shares Bought by Cambridge Investment Research Advisors Inc.” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/20/biogen-inc-biib-shares-bought-by-cambridge-investment-research-advisors-inc.html.

Several equities research analysts recently issued reports on BIIB shares. BidaskClub raised Biogen from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Vetr raised Biogen from a “hold” rating to a “buy” rating and set a $319.53 price objective for the company in a research note on Monday, July 31st. Cowen and Company reissued a “buy” rating on shares of Biogen in a research note on Thursday, July 27th. Deutsche Bank AG reissued a “buy” rating and issued a $319.00 price objective (up from $315.00) on shares of Biogen in a research note on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) raised Biogen from a “neutral” rating to a “buy” rating and raised their price target for the stock from $228.00 to $338.00 in a research note on Wednesday, July 26th. Twelve investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $341.89.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply